Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Vasomotor Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Vasomotor Symptoms Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Lynkuet (elinzanetant 60 mg) and Veozah (fezolinetant 45 mg) for vasomotor symptoms, including initial and renewal therapy. It applies to commercial plan members and requires clinical criteria and, when applicable, justification for quantities above the program limit.

    Policy Summary
    PayerPrime Therapeutics
    PolicyVasomotor Symptoms Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required clinical history, treatment history, and baseline hepatic function results before starting therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 agentsTargeted drugs
    60/30dLynkuet limit
    30/30dVeozah limit
    3 moInitial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 moRenewal approval
    7+/daySymptom threshold

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The patient has a diagnosis of vasomotor symptoms and ALL of the following

        • The patient is menopausal.
        • The patient's symptoms are moderate to severe (i.e., 7 or more episodes per day or 50 or more episodes per week).
        • BOTH of the following

          • Baseline (prior to starting the requested agent) hepatic function (i.e., serum ALT, serum AST, serum ALP, serum bilirubin [total and direct]) has been evaluated.
          • Hepatic transaminases and total bilirubin are less than 2 times the upper limit of normal (ULN).
        • ONE of the following

          • Tried and had an inadequate response to ONE hormonal therapy (i.e., estrogen therapy [ET] or estrogen plus progesterone therapy [EPT], including oral, transdermal patches, sprays and gels, and vaginal ring agents) used to treat vasomotor symptoms of menopause.
          • An intolerance or hypersensitivity to ONE hormonal therapy used to treat vasomotor symptoms of menopause.
          • An FDA-labeled contraindication to ALL hormonal therapies used to treat vasomotor symptoms of menopause.
          • An age over 60 years.
          • An onset of menopause that was at least 10 years prior.
        • ONE of the following

          • Tried and had an inadequate response to ONE nonhormonal therapy (i.e., paroxetine, escitalopram, citalopram, venlafaxine, desvenlafaxine, duloxetine, gabapentin, or oxybutynin) used to treat vasomotor symptoms of menopause.
          • An intolerance or hypersensitivity to ONE nonhormonal therapy used to treat vasomotor symptoms of menopause.
          • An FDA-labeled contraindication to ALL nonhormonal therapies used to treat vasomotor symptoms of menopause.
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Renewal Therapy

    Renewal therapy will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent will require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • ALL of the following

      • Hepatic function (i.e., serum ALT, serum AST, serum ALP, serum bilirubin [total and direct]) has been evaluated since starting the requested agent.
      • Hepatic transaminases are less than 5 times the upper limit of normal (ULN).

    Quantity-Limit Exception

    Approval above the program quantity limit requires ALL of the following:

    ALL of the following

    • The requested quantity (dose) exceeds the program quantity limit.
    • ONE of the following

      • BOTH of the following

        • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • BOTH of the following

        • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.

    The requested agent is not covered when the patient has any FDA-labeled contraindication to the requested agent.

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for targeted agents Lynkuet (elinzanetant 60 mg) and Veozah (fezolinetant 45 mg). Initial approval may follow the vasomotor-symptom pathway or another FDA-labeled indication for the requested agent and route; the requested agent must not have an FDA-labeled contraindication.

    • Submit documentation supporting the applicable initial pathway and all clinical criteria.
    • Initial approval length: 3 months; renewal approval length: 12 months.
    • Refer to the Quantity Limit Criteria when a quantity limit applies.
    Step Therapy

    Document Hormonal and Nonhormonal Therapy History

    Document the required hormonal and nonhormonal treatment history, including the applicable exception when a trial is not clinically appropriate.

    • Hormonal pathway: inadequate response to one hormonal therapy; intolerance or hypersensitivity to one hormonal therapy; an FDA-labeled contraindication to all hormonal therapies; age over 60 years; or menopause onset at least 10 years prior.

    Policy Background

    This policy addresses pharmacologic treatment of menopausal vasomotor symptoms with nonhormonal agents. Under the vasomotor-symptom pathway, coverage is directed to menopausal patients with moderate-to-severe symptoms, defined as 7 or more episodes per day or 50 or more episodes per week. The clinical pathway generally requires an inadequate response, intolerance, hypersensitivity, or applicable contraindication involving hormonal and nonhormonal therapies, along with baseline hepatic evaluation before treatment. For renewal, clinical benefit and follow-up hepatic monitoring are required.

    Clinical Definitions

    Moderate-to-severe symptoms
    Daily threshold7 or more episodes per day
    Weekly threshold50 or more episodes per week
    Symptom classificationModerate-to-severe vasomotor symptoms
    Baseline hepatic function
    Alanine aminotransferase (ALT)Serum ALT
    Aspartate aminotransferase (AST)Serum AST
    Alkaline phosphatase (ALP)Serum ALP

    Initial Therapy

    Continuation Therapy

    Continuation Criteria

    Continuation approval requires ALL of the following, with supporting evidence of treatment response and hepatic monitoring.

    Continuation requirements

    • The patient was previously approved for the requested agent through the plan's prior authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent; submit supporting evidence of benefit.

      Document the patient's response to therapy.

    • Hepatic monitoring

      • Hepatic function has been evaluated since starting the requested agent, including serum ALT, serum AST, serum ALP, and total and direct bilirubin.

        Submit post-treatment hepatic function results.

    Step-Therapy Requirements

    StepTherapy requirementExceptions or alternativesSupporting conditions
    1Try one hormonal therapy used to treat menopausal vasomotor symptoms and demonstrate an inadequate response.The requirement may be met by intolerance or hypersensitivity to one hormonal therapy; an FDA-labeled contraindication to all hormonal therapies; age over 60 years; or menopause onset at least 10 years earlier.Applicable therapies include estrogen therapy or estrogen plus progesterone therapy, including oral, transdermal patch, spray, gel, and vaginal-ring agents.
    2Try one nonhormonal therapy used to treat menopausal vasomotor symptoms and demonstrate an inadequate response.The requirement may be met by intolerance or hypersensitivity to one nonhormonal therapy or an FDA-labeled contraindication to all nonhormonal therapies.Applicable therapies include paroxetine, escitalopram, citalopram, venlafaxine, desvenlafaxine, duloxetine, gabapentin, and oxybutynin; the patient must have a diagnosis of vasomotor symptoms and meet the menopausal, symptom-severity, and baseline hepatic requirements.

    Program Quantity Limits

    Lynkuet (elinzanetant) 60 mg capsule
    Quantity limit60 capsules per 30 days
    Strength and form60 mg capsule
    Veozah (fezolinetant) 45 mg tablet
    Quantity limit30 tablets per 30 days
    Strength and form45 mg tablet
    Policy Summary
    PayerPrime Therapeutics
    PolicyVasomotor Symptoms Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required clinical history, treatment history, and baseline hepatic function results before starting therapy.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationPolicy BackgroundClinical DefinitionsInitial TherapyContinuation TherapyStep-Therapy RequirementsProgram Quantity Limits
    The patient does NOT have any FDA-labeled contraindications to the requested agent.
  1. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  2. BOTH of the following

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  3. Hormonal therapies include estrogen therapy or estrogen-plus-progesterone therapy, including oral, transdermal patch, spray, gel, and vaginal ring agents.
  4. Nonhormonal pathway: inadequate response to one nonhormonal therapy; intolerance or hypersensitivity to one nonhormonal therapy; or an FDA-labeled contraindication to all nonhormonal therapies.
  5. Examples of nonhormonal therapies include paroxetine, escitalopram, citalopram, venlafaxine, desvenlafaxine, duloxetine, gabapentin, and oxybutynin.
  6. Documentation Required

    Submit Clinical and Treatment History

    For the vasomotor-symptom pathway, document the diagnosis, menopausal status, symptom severity, and relevant treatment history supporting the request.

    • Diagnosis of vasomotor symptoms.
    • Patient is menopausal.
    • Symptoms are moderate to severe: 7 or more episodes per day or 50 or more episodes per week.
    • Document the applicable hormonal and nonhormonal treatment trial, intolerance, hypersensitivity, contraindication, age, or timing-of-menopause exception.
    • If requesting under another FDA-labeled indication, document the indication and that the requested route of administration is FDA labeled.
    Documentation Required

    Document Baseline Hepatic Evaluation

    Before starting the requested agent, obtain and document baseline hepatic function. The baseline results must show hepatic transaminases and total bilirubin below the specified safety threshold.

    • Obtain serum ALT, serum AST, serum ALP, and total and direct serum bilirubin.
    • Hepatic transaminases and total bilirubin must be less than 2 times the upper limit of normal (ULN).
    Documentation Required

    Renewal Requires Benefit and Hepatic Monitoring

    For renewal, document that the patient has experienced clinical benefit and provide follow-up hepatic testing obtained after treatment began.

    • The patient must have been previously approved through the plan's prior authorization process.
    • Document clinical benefit with the requested agent.
    • Repeat and submit serum ALT, serum AST, serum ALP, and total and direct serum bilirubin results.
    • Hepatic transaminases must be less than 5 times the ULN.
    Documentation Required

    Support Quantity-Limit Exceptions

    A quantity above the program limit requires specific support. Submit documentation showing why the requested quantity or dose is medically necessary under one of the permitted quantity-limit pathways.

    • If there is no maximum FDA-labeled dose for the indication, support therapy with a higher dose.
    • If the requested dose does not exceed the maximum FDA-labeled dose, explain why it cannot be achieved with a lower quantity of a higher-strength product that remains within the program quantity limit.
    • If the requested dose exceeds the maximum FDA-labeled dose, provide support for therapy with the higher dose.
    • Quantity-limit approval length: 3 months for initial approval and 12 months for renewal.
    Denial Risk

    Failure to Meet Criteria May Result in Denial

    Requests are at risk for denial when the applicable clinical pathway, treatment history, hepatic safety requirements, or contraindication requirements are not met.

    • The patient must satisfy the vasomotor-symptom pathway or have another FDA-labeled indication for the requested agent and route.
    • Required hormonal and nonhormonal treatment trials or an applicable exception must be documented.
    • Required hepatic laboratory results must meet the applicable initial or renewal thresholds.
    • The patient must not have an FDA-labeled contraindication to the requested agent.
    Denial Risk

    Initial Criteria Not Met

    Initial approval for the vasomotor-symptom pathway may be denied when the required diagnosis, menopausal status, symptom severity, hepatic evaluation, treatment history, or safety criteria are not documented or met.

    • No documented vasomotor-symptom diagnosis or menopausal status.
    • Symptoms do not meet the moderate-to-severe threshold of 7 or more episodes per day or 50 or more episodes per week.
    • Required hormonal or nonhormonal therapy trial, intolerance, hypersensitivity, contraindication, age, or menopause-timing exception is not established.
    • Baseline hepatic function is not evaluated or hepatic transaminases or total bilirubin are 2 or more times the ULN.
    • An FDA-labeled contraindication to the requested agent is present.
    Denial Risk

    Renewal Criteria Not Met

    Continuation approval may be denied when prior plan approval, clinical benefit, or required post-treatment hepatic monitoring is not established.

    • The patient was not previously approved through the plan's prior authorization process.
    • Clinical benefit with the requested agent is not documented.
    • Post-treatment hepatic function has not been evaluated.
    • Hepatic transaminases are 5 or more times the ULN.
    Denial Risk

    Sample Use Does Not Establish Renewal Eligibility

    Treatment begun with samples does not satisfy the recent-treatment requirement for renewal eligibility. The prescriber must state that the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed.

    • Starting therapy with samples is explicitly not approvable for this purpose.
    • Document treatment with the requested agent—not merely sample use—within the past 90 days.
    • Document that the patient is at risk if therapy is changed.
    Denial Risk

    Unsupported Quantity-Limit Exception May Be Denied

    A request for a quantity above the program limit may be denied unless the submission contains support for one of the permitted quantity-limit exceptions.

    • Support a higher dose when no maximum FDA-labeled dose exists for the indication.
    • Explain why a lower quantity of a higher-strength product within the program limit cannot achieve the requested dose when the requested dose is within the FDA-labeled maximum.
    • Provide support for therapy above the FDA-labeled maximum when the requested dose exceeds that maximum.
    • Unsupported excess quantities do not qualify for approval.
    BilirubinSerum bilirubin, both total and direct
    Hepatic transaminases are less than 5 times the ULN.Less than 5 times ULN
  7. Safety requirement

    • The patient does not have any FDA-labeled contraindications to the requested agent.